Natera NTRA recently announced a major upgrade to its Panorama non-invasive prenatal test (NIPT). Powered by the company’s ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new collaboration with Diakonos Oncology Corp., a clinical-stage biotechnology company ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced enrollment of the first ...

Natera (NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, and Biopticka Laborator, one of the largest and most well-established laboratories in the Czech ...

Natera NTRA recently announced a major expansion of its operations in Austin, TX, as part of its growth strategy and ...

Natera gets a buy rating reaffirmed, driven by robust expansion plans, recent FDA approval, and upgraded FY26 revenue ...

Natera (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, visits the Nasdaq MarketSite in Times Square. The event marks Natera’s 10th year as a publicly traded company. Natera ...

The test will enable physicians to assess if post-surgery cancer patients need to receive treatment to minimize the risk of ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA ...

During the quarter, we added 9 new positions and exited 11 positions, bringing the number of positions in the Fund to 41.

A jury ruled that Natera, a cell-free DNA testing company, and its executives recklessly and intentionally misrepresented the benefits of Natera’s kidney transplant rejection assessment test: Prospera ...